Expert Opinion on Emerging Drugs最新文献_第10页

Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials. 用于治疗镰状细胞病的新兴药物:II/III期试验综述

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-06-01 Epub Date: 2022-08-01 DOI: 10.1080/14728214.2022.2105835

Jules M Ross, Stéphanie Forté, Denis Soulières

{"title":"Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.","authors":"Jules M Ross, Stéphanie Forté, Denis Soulières","doi":"10.1080/14728214.2022.2105835","DOIUrl":"https://doi.org/10.1080/14728214.2022.2105835","url":null,"abstract":"Introduction: The substitution of glutamic acid by valine on the ß-globin chain produces the hemoglobin S variant responsible for sickle cell disease (SCD), a disorder that affects millions of people worldwide and leads to acute and cumulative organ damage. Even though life expectancy has significantly improved where the best medical care is available, there are still few therapeutic options for SCD and those are limited by their availability, cost, and individual toxicities.Areas covered: This review summarizes the clinical data on current treatments for SCD and emerging therapies studied in the acute setting as well as potential disease-modifying agents, with an emphasis on the FDA-approved agents.Expert opinion: Hydroxyurea has been a gold standard for two decades, showing benefits in acute complications and overall survival in sickle cell anemia, although data is lacking for certain genotypes such as hemoglobin SC. As progress is made in our understanding of the pathophysiological networks characterizing SCD, numerous pathways appear to be targetable, with L-glutamine, crizanlizumab and voxelotor now approved by the FDA. Pursuing a multi-agent approach could alter the disease course in a more effective fashion and provide an alternative option to curative therapies, but longer clinical studies are needed.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"211-224"},"PeriodicalIF":3.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40662674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials 表皮生长因子受体靶向治疗非小细胞肺癌:II期和III期试验综述

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-04-03 DOI: 10.1080/14728214.2022.2063836

Hong-Lian Lu, G. Jie, Yi‐Long Wu

{"title":"Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials","authors":"Hong-Lian Lu, G. Jie, Yi‐Long Wu","doi":"10.1080/14728214.2022.2063836","DOIUrl":"https://doi.org/10.1080/14728214.2022.2063836","url":null,"abstract":"ABSTRACT Introduction Epidermal growth factor receptor (EGFR) is one of the most common driver gene mutations in non-small-cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitors (TKIs) monotherapy and EGFR-TKI combined with chemotherapy or anti-angiogenesis drugs have significantly prolonged the survival of patients with EGFR-mutant NSCLC. However, disease progression caused by acquired resistance to EGFR-TKIs is inevitable. And patients with EGFR exon 20ins showed limited efficacy to EGFR-TKIs. Areas covered In this review, we initially evaluated the efficacy of existing treatments for EGFR-mutant NSCLC. Second, we reviewed the ongoing phase II and III clinical trials, provided the latest results, discussed the scientific rationale of these trials and the potential development issues. Expert opinion The application of EGFR-TKIs has greatly changed the therapeutic strategies for advanced and resected NSCLC with EGFR mutations, and the 5-year overall survival (OS) rate for advanced NSCLC was close to 40%. The current research direction for the treatment of patients with EGFR mutations focuses on the following three aspects: uncommon EGFR mutation subtypes, brain metastases, and EGFR TKI-based combination therapy. Future studies on EGFR-mutant NSCLC therapy will focus on overcoming EGFR-TKI-related resistance, preventing drug resistance in advance, and developing bispecific antibody drugs.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 1","pages":"111 - 126"},"PeriodicalIF":3.4,"publicationDate":"2022-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47773104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials 评估乙型肝炎治疗药物治疗的发展前景：II期临床试验中药物的关注

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-04-03 DOI: 10.1080/14728214.2022.2074977

R. Hui, L. Mak, W. Seto, M. Yuen

{"title":"Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials","authors":"R. Hui, L. Mak, W. Seto, M. Yuen","doi":"10.1080/14728214.2022.2074977","DOIUrl":"https://doi.org/10.1080/14728214.2022.2074977","url":null,"abstract":"ABSTRACT Introduction Functional cure, defined as sustained HBsAg seroclearance, is associated with favorable outcomes in chronic hepatitis B (CHB). While nucleos(t)ide analogues (NAs) are effective in suppressing HBV replication, NAs are unable to induce functional cure at high rates. A range of novel HBV antivirals, aiming to induce functional cure, are currently under development. Areas covered This article covered novel hepatitis B virus (HBV) antivirals that have entered phase II trials. Virus-directing agents covered include entry inhibitors, transcription inhibitors, RNA silencers, core protein allosteric modulators, noncompetitive polymerase inhibitors, and viral protein export inhibitors. Immunomodulators covered include innate immune stimulators, T-cell modulators, therapeutic vaccines, and monoclonal antibodies. Upcoming developmental directions would also be discussed. Expert opinion Among novel HBV antivirals, RNA silencers, viral protein export inhibitors (with pegylated interferon), and entry inhibitors (with pegylated interferon) appear to be effective in suppressing HBsAg and may even induce functional cure. The other virus-targeting agents have variable effects on HBV DNA, HBsAg, HBeAg, and HBcrAg. Immunomodulators have modest effects on HBsAg but may have important roles in combination therapy. Upcoming trials will answer important questions on ideal dosing, long-term drug effects, and efficacy of combination regimens.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 1","pages":"127 - 140"},"PeriodicalIF":3.4,"publicationDate":"2022-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41594487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Emerging drugs for the treatment of hepatocellular carcinoma 治疗肝细胞癌的新兴药物

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-04-03 DOI: 10.1080/14728214.2022.2083107

W. Ayoub, Patricia D. Jones, J. D. Yang, Paul M. Martin

{"title":"Emerging drugs for the treatment of hepatocellular carcinoma","authors":"W. Ayoub, Patricia D. Jones, J. D. Yang, Paul M. Martin","doi":"10.1080/14728214.2022.2083107","DOIUrl":"https://doi.org/10.1080/14728214.2022.2083107","url":null,"abstract":"ABSTRACT Introduction Hepatocellular carcinoma (HCC) remains a leading cause of liver-related mortality. Cirrhosis of any etiology is the major risk factor although HCC can develop in its absence in patients with hepatitis B and increasingly in those with nonalcoholic fatty liver disease. When detected at an early stage, curative options include surgical resection, liver transplantation, and/or ablative therapies. Unfortunately, most cases of HCC are recognized at an advanced stage when options are limited and noncurative. However, new systemic therapies with tyrosine kinase inhibitors and immunotherapy have expanded therapeutic options in advanced HCC. Advances in systemic therapy have given patients with advanced HCC hope and prolonged their survival. Areas covered We discuss recent data and ongoing research efforts to improve the treatment of hepatocellular carcinoma with discussion of current and upcoming systemic therapies combining agents of different classes. Expert opinion Systemic therapy for HCC is in evolution. The inclusion of immunotherapy to systemic therapy has revolutionized the field of HCC treatment. Identification of the appropriate combination and sequence of systemic therapy coupled with discovery of reliable HCC biomarkers will lead to improved survival and individualized HCC therapy.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 1","pages":"141 - 149"},"PeriodicalIF":3.4,"publicationDate":"2022-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45627778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials. 癫痫:专家对2/3期临床试验新兴药物的意见

IF 2.7 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-03-01 Epub Date: 2022-04-01 DOI: 10.1080/14728214.2022.2059464

Amanda W Pong, Jonathan Ross, Ivana Tyrlikova, Alexander J Giermek, Maya P Kohli, Yousef A Khan, Roger D Salgado, Pavel Klein

{"title":"Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials.","authors":"Amanda W Pong, Jonathan Ross, Ivana Tyrlikova, Alexander J Giermek, Maya P Kohli, Yousef A Khan, Roger D Salgado, Pavel Klein","doi":"10.1080/14728214.2022.2059464","DOIUrl":"10.1080/14728214.2022.2059464","url":null,"abstract":"Introduction: Despite the existence of over 30 anti-seizure medications (ASM), including 20 over the last 30 years, a third of patients with epilepsy remain refractory to treatment, with no disease-modifying or preventive therapies until very recently. The development of new ASMs with new mechanisms of action is therefore critical. Recent clinical trials of new treatments have shifted focus from traditional common epilepsies to rare, genetic epilepsies with known mechanistic targets for treatment and disease-specific animal models.Areas covered: ASMs in phase 2a/b-3 clinical trials target cholesterol, serotonin, sigma-1 receptors, potassium channels and metabotropic glutamate receptors. Neuroinflammation, protein misfolding, abnormal thalamocortical firing, and molecular deficiencies are among the targeted pathways. Clinically, the current phase 2a/b-3 agents hold promise for variety of epilepsy conditions, from developmental epileptic encephalopathies (Dravet Syndrome, Lennox-Gastaut syndrome, CDKL5 and PCDH19, Rett's Syndrome), infantile spasms, tuberous sclerosis as well as focal and idiopathic generalized epilepsies and acute rescue therapy for cluster seizures.Expert opinion: New delivery mechanisms increase potency and site-specificity of existing drugs. Novel mechanisms of action involve cholesterol degradation, mitochondrial pathways, anti-inflammation, and neuro-regeneration. Earlier identification of genetic conditions through genetic testing will allow for earlier use of disease specific and disease-modifying therapies.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 1","pages":"75-90"},"PeriodicalIF":2.7,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48611252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. 新出现的FLT3抑制剂治疗急性髓性白血病。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-03-01 Epub Date: 2022-01-25 DOI: 10.1080/14728214.2021.2009800

Antonio Solana-Altabella, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos

{"title":"Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.","authors":"Antonio Solana-Altabella, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos","doi":"10.1080/14728214.2021.2009800","DOIUrl":"https://doi.org/10.1080/14728214.2021.2009800","url":null,"abstract":"Introduction: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with Acute Myeloid Leukemia (AML). Midostaurin, quizartinib, and gilteritinib have been approved in the last years for the treatment of AML, and more Tyrosine Kinase Inhibitors (TKIs) targeting FLT3 are being developed such as crenolanib.Areas covered: In this systematic review, we will analyze the available clinical data on FLT3 inhibitors in development and describe the potential role that these FLT3-TKIs may play in the future management of FLT3-mutated (FLT3mut) AML.Expert opinion: Although several aspects may challenge the use of FLT3 inhibitors in AML (resistance mechanisms, on- and off-target toxicities or drug-drug interactions), these drugs are generally well tolerated, particularly if we compare their safety profile with classical chemotherapy agents or even with newer immunotherapies, thus enabling their use in fit and unfit AML patients, alone or combined. As AML is a polyclonal disease and FLT3 mutations are a late leukemogenic event, combinations of these FLT3 inhibitors with other antileukemic agents (like venetoclax or hypomethylating agents) seem a necessary research pathway.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-18"},"PeriodicalIF":3.4,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39947123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. 治疗阵发性夜间血红蛋白尿的新药物。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-03-01 Epub Date: 2022-01-31 DOI: 10.1080/14728214.2022.2031973

Camilla Frieri, Régis Peffault de Latour, Flore Sicre De Fontbrune

{"title":"Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.","authors":"Camilla Frieri, Régis Peffault de Latour, Flore Sicre De Fontbrune","doi":"10.1080/14728214.2022.2031973","DOIUrl":"https://doi.org/10.1080/14728214.2022.2031973","url":null,"abstract":"Introduction: Eculizumab, the first anti-C5 monoclonal antibody approved for patients with paroxysmal nocturnal hemoglobinuria (PNH), has revolutionized the natural history of this disease, blocking intravascular hemolysis, reducing the risk of thromboembolic events, resulting in a significant improvement in survival and quality of life. However, the hematological response to eculizumab is extremely heterogeneous, with only one-third of PNH patients reaching normal hemoglobin levels.Areas covered: This article reviews the current new drugs being investigated in phase II and III trials for adult PNH patients. Literature search was performed using Medline and Clinicaltrials.org databases.Expert opinion: The new molecules have been classified according to the target of the complement system on which they act; we have novel terminal complement inhibitors, which target C5, and proximal complement inhibitors, which interfere with C3 or even further upstream (factor B and D). Ravulizumab is the first next-generation C5 inhibitor, approved by FDA and EMA, which reproduced the excellent results achieved with eculizumab, trying to improve the convenience of patients. However, unresolved issues remain, such as C3-mediated extravascular hemolysis, on which novel proximal complement inhibitors are showing their efficacy. Pegcetacoplan is the first C3-inihibitor approved by FDA. Long-term safety data for novel complement inhibitors are needed.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"33-43"},"PeriodicalIF":3.4,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39963517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Emerging drugs for the treatment of cutaneous T-cell lymphoma. 治疗皮肤t细胞淋巴瘤的新药物。

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-03-01 DOI: 10.1080/14728214.2022.2049233

Melissa Cheng, Jasmine Zain, Steven T Rosen, Christiane Querfeld

{"title":"Emerging drugs for the treatment of cutaneous T-cell lymphoma.","authors":"Melissa Cheng, Jasmine Zain, Steven T Rosen, Christiane Querfeld","doi":"10.1080/14728214.2022.2049233","DOIUrl":"https://doi.org/10.1080/14728214.2022.2049233","url":null,"abstract":"Introduction: Cutaneous T cell lymphoma (CTCL) is a rare and incurable group of non-Hodgkin lymphomas that manifest as patches, plaques, tumors, and/or erythroderma in the skin. Standard skin-directed therapies for CTCL are effective in patients with indolent early-stage disease, but more advanced/refractory stage patients require systemic therapies. However, none of the treatments are considered curative and most patients suffer from relapses. Biologic therapies and immunotherapy provide novel treatment options for patients with advanced or refractory disease.Areas covered: This review provides a discussion of recently approved biological and novel therapeutics that are actively developed for the management of the heterogeneous group of CTCL.Expert opinion: Mogamulizumab and brentuximab vedotin have reached the market and are approved for the treatment of CTCL, providing valuable options. Additionally, therapies utilizing immune checkpoint inhibitors, miRNA inhibitors, and peptide inhibitors show promising results in clinical trials. Durvalumab, pembrolizumab, TTI-621, BNZ-1, and MRG-106 are several of the emerging treatments still in trials. Further combinatorial studies are needed as none of the treatments have demonstrated long-term remissions.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 1","pages":"45-54"},"PeriodicalIF":3.4,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320301/pdf/nihms-1905596.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9754829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Recent advances in immune-based approaches for the treatment of esophagogastric cancer. 基于免疫方法治疗食管胃癌的最新进展

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-03-01 Epub Date: 2022-01-03 DOI: 10.1080/14728214.2021.2020757

C S Weadick, A G Duffy, R J Kelly

{"title":"Recent advances in immune-based approaches for the treatment of esophagogastric cancer.","authors":"C S Weadick, A G Duffy, R J Kelly","doi":"10.1080/14728214.2021.2020757","DOIUrl":"https://doi.org/10.1080/14728214.2021.2020757","url":null,"abstract":"Introduction: The year 2021 will be remembered as a transformational year in the management of both esophageal and gastric cancers. Decades of failed clinical trials had seen limited therapeutic advances beyond refinement of the traditional combined modality approach. Targeted strategies against specific molecular alterations did not - with the exception of Her2 - yield the desired breakthroughs, and it was unclear what immune-based approaches would bring to this group of cancers. The presence of tumor-infiltrating lymphocytes in esophagogastric cancer demonstrates that an endogenous immune response is already occurring and potentially amplifiable by immune checkpoint inhibition. Recent data have validated this with FDA approvals in both the locoregional (CheckMate 577) and metastatic disease (CheckMate 649, KeyNote 590 and KeyNote 811) setting which have altered the therapeutic landscape.Areas covered: Here we discuss recent data and ongoing research efforts to better define the role of immune-based approaches and select the patient cohorts who might gain the most benefit from them.Expert opinion: Immunotherapy, and specifically the incorporation of the immune checkpoint inhibitors (ICI) drug class, has altered the therapeutic paradigm of many cancers in recent years. Anti-PD-1 therapies are now the new standard of care for patients with local and advanced disease.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"19-31"},"PeriodicalIF":3.4,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39747565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Emerging therapies in the management of Irritable Bowel Syndrome (IBS) 肠易激综合征（IBS）治疗的新兴疗法

IF 3.4 3区医学

Expert Opinion on Emerging Drugs Pub Date : 2022-01-02 DOI: 10.1080/14728214.2022.2052043

J. Elwing, Hadi Atassi, Benjamin D. Rogers, G. Sayuk

{"title":"Emerging therapies in the management of Irritable Bowel Syndrome (IBS)","authors":"J. Elwing, Hadi Atassi, Benjamin D. Rogers, G. Sayuk","doi":"10.1080/14728214.2022.2052043","DOIUrl":"https://doi.org/10.1080/14728214.2022.2052043","url":null,"abstract":"ABSTRACT Introduction Irritable bowel syndrome (IBS) is a symptom-based disorder of chronic abdominal pain and altered bowel habits. The pathogenesis of IBS is multifactorial, leading to the potential for the development of diverse treatment strategies. This mechanistic heterogeneity suggests that available therapies will only prove effective in a subset of IBS sufferers. Current US Food and Drug Administration (FDA) approved therapies for IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C) are reviewed. Limited symptom responses and side effect experiences lead to considerable patient dissatisfaction with currently available IBS treatments. Only a small percentage of IBS patients are on prescription therapies underscoring the potential market and need for additional therapeutic options. Areas covered Expanding on currently available therapies, the serotonergic and endogenous opioid receptor systems continue to be a focus of future IBS treatment development. Additional novel emerging therapies include the endogenous cannabinoid system, bile acid secretion and sequestration, and exploit our enhanced understanding of visceral sensory signaling and intestinal secretomotor function. Expert opinion While challenges remain for the future development of IBS therapies, the diverse etiologies underlying the disorder present an opportunity for novel therapies. Hence, great potential is anticipated for future IBS treatment options.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":"27 1","pages":"55 - 73"},"PeriodicalIF":3.4,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45584212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0